A phase II clinical trial conducted in China reported for the first time that Imatinib was effective in prolonging the PFS of advanced metastatic MM patients caused by KIT mutations and in improving the rate of disease control and treatment efficiency [51]. Here, KIT is linked to Miyoshi myopathy.